The burden of alcohol-related cirrhosis (AC) among women has decreased but is disproportionately high in lower Sociodemographic Index (SDI) regions.

In a best practice guideline, advice is presented for clinicians regarding the benefits and harms of cannabis or cannabinoids for the management of chronic noncancer pain.

The association between screen time and depression seen among adolescents is potentially mediated by poor sleep.

The rates of respondent dissatisfaction with current hidradenitis suppurativa (HS) treatment options are high.

Hormone diets have taken off on social media as the latest weight loss trend, but their scientific validity remains questionable.

Community-level SDOH such as household income, neighborhood walkability, and healthcare access play a greater role in predicting THA outcomes than patient race.

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.

Postoperative pain and opioid consumption were increased among patients who underwent TKA but decreased among those who underwent THA.

The following is a recap of updates that occurred in March 2025 related to drugs in the development pipeline. The table below is a review of notable updates that occurred in March 2025 for ...

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

In racially and socioeconomically marginalized pediatric patients there are significant inequities in the incidence of HER behavioral flags.